Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Arbutus Biopharma Corp | Chief Financial Officer | Common Shares | 182K | $421K | $2.31 | Feb 2, 2024 | Direct |
SCYNEXIS INC | Director | Common Stock | 46.2K | $75.3K | $1.63 | Jun 20, 2024 | Direct |
Arbutus Biopharma Corp | Chief Financial Officer | Stock Option (Right to Buy) | 450K | Feb 1, 2024 | Direct | ||
SCYNEXIS INC | Director | Stock Option | 23K | Jun 20, 2024 | Direct | ||
Entasis Therapeutics Holdings Inc. | Director | Common Stock | 0 | $2.20 | Jul 11, 2022 | Direct | |
Entasis Therapeutics Holdings Inc. | Director | Stock Option (right to buy) | 0 | Jul 11, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SCYX | SCYNEXIS INC | Jun 20, 2024 | 2 | $0 | 4 | Jun 21, 2024 | Director |
ABUS | Arbutus Biopharma Corp | Feb 1, 2024 | 3 | -$22.2K | 4 | Feb 5, 2024 | Chief Financial Officer |
SCYX | SCYNEXIS INC | Jun 15, 2023 | 1 | $0 | 4 | Jun 23, 2023 | Director |
SCYX | SCYNEXIS INC | Jun 15, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Director |
ABUS | Arbutus Biopharma Corp | Feb 1, 2023 | 2 | $0 | 4 | Feb 3, 2023 | Chief Financial Officer |
VBLT | Vascular Biogenics Ltd. | Jan 1, 2023 | 0 | $0 | 3 | Jan 3, 2023 | Director |
ETTX | Entasis Therapeutics Holdings Inc. | Jul 7, 2022 | 4 | -$109K | 4 | Jul 11, 2022 | Director |
SCYX | SCYNEXIS INC | Jun 17, 2022 | 2 | $0 | 4 | Jun 22, 2022 | Director |
ABUS | Arbutus Biopharma Corp | Jan 20, 2022 | 1 | $801K | 4 | Jan 20, 2022 | Chief Financial Officer |
ETTX | Entasis Therapeutics Holdings Inc. | Jan 18, 2022 | 1 | $0 | 4 | Jan 19, 2022 | Director |
ETTX | Entasis Therapeutics Holdings Inc. | Jul 16, 2021 | 6 | $0 | 4 | Feb 15, 2022 | Director |
SCYX | SCYNEXIS INC | Jun 16, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |